2023 was a tricky yr with the biopharma sector, with several organizations downsizing and restructuring their workforces to remain afloat. You will find signs of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences marketplace during the latter part of 2023 and have continued their https://sites.google.com/view/bio-sites/blog